Rong Wang
25Patents
11h-index
30Co-inventors
75Inventor score
Filing activity: Jun 7, 1995 → Mar 3, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5840839A | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein | Emerging Cross-Sectional Technologies | 137 | Expired |
| US5792664A | Methods for producing and analyzing biopolymer ladders | Emerging Cross-Sectional Technologies | 57 | Expired |
| US5831016A | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes | Emerging Cross-Sectional Technologies | 51 | Expired |
| US7632499B2 | Anti-myostatin antibodies | Chemistry; Metallurgy | 49 | Active |
| US7635760B2 | Anti-myostatin antibodies | Emerging Cross-Sectional Technologies | 28 | Active |
| US7619057B2 | MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 | Emerging Cross-Sectional Technologies | 23 | Expired |
| US6132980A | Antibodies specific for TRP-2 a human tumor antigen recognized by cytotoxic T lymphocytes | Emerging Cross-Sectional Technologies | 19 | Expired |
| US7745583B2 | Anti-myostatin antibodies | Emerging Cross-Sectional Technologies | 19 | Active |
| US6271037A | Method and product for the sequence determination of peptides using a mass spectrometer | Emerging Cross-Sectional Technologies | 13 | Expired |
| US8754046B2 | MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1 | Emerging Cross-Sectional Technologies | 12 | Active |
| US6083703A | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes | Chemistry; Metallurgy | 12 | Expired |
| US8066995B2 | Anti-myostatin antibodies | Chemistry; Metallurgy | 9 | Active |
| US6750061B2 | Method and product for the sequence determination of peptides using a mass spectrometer | Emerging Cross-Sectional Technologies | 9 | Expired |
| US7084239B1 | Cancer peptides of NY-ESO-1/CAG-3 | Human Necessities | 8 | Expired |
| US6087110A | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein | Emerging Cross-Sectional Technologies | 8 | Expired |
| US6800613B2 | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds | Chemistry; Metallurgy | 4 | Expired |
| US7902159B2 | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds | Chemistry; Metallurgy | 3 | Active |
| US8211445B2 | PSM peptides as vaccine targets against methicillin-resistant Staphylococcus | Physics | 2 | Active |
| US8318697B2 | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds | Chemistry; Metallurgy | 2 | Active |
| US7001600B1 | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes | Human Necessities | 0 | Expired |
| US7015312B1 | Antibodies to the protein product encoded by ORF3 of the TRP-1 gene and compositions and kits thereof | Human Necessities | 0 | Expired |
| US10251912B2 | MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 | Emerging Cross-Sectional Technologies | 0 | Active |
| US11707724B2 | Preparation method of bacterial cellulose-defective molybdenum disulfide heterojunction material for treating radioactive wastewater | Emerging Cross-Sectional Technologies | 0 | Active |
| US7341874B2 | Method for detecting post-translation modifications of peptides | Emerging Cross-Sectional Technologies | 0 | Expired |
| US9447144B2 | MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.